nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS2—urinary bladder cancer	0.63	1	CbGaD
Nepafenac—PTGS2—Cisplatin—urinary bladder cancer	0.105	0.356	CbGbCtD
Nepafenac—PTGS2—Etoposide—urinary bladder cancer	0.103	0.349	CbGbCtD
Nepafenac—PTGS1—Etoposide—urinary bladder cancer	0.0871	0.295	CbGbCtD
Nepafenac—Scab—Fluorouracil—urinary bladder cancer	0.00169	0.0519	CcSEcCtD
Nepafenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00165	0.0505	CbGpPWpGaD
Nepafenac—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	0.00153	0.0467	CbGpPWpGaD
Nepafenac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00131	0.0401	CbGpPWpGaD
Nepafenac—Diclofenac—UGT2B7—urinary bladder cancer	0.00124	0.167	CrCbGaD
Nepafenac—Ocular discomfort—Methotrexate—urinary bladder cancer	0.00123	0.0378	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00112	0.0343	CbGpPWpGaD
Nepafenac—Carbamazepine—UGT2B7—urinary bladder cancer	0.00106	0.143	CrCbGaD
Nepafenac—Lacrimation—Fluorouracil—urinary bladder cancer	0.000913	0.0281	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000891	0.0272	CbGpPWpGaD
Nepafenac—Blepharitis—Fluorouracil—urinary bladder cancer	0.000873	0.0269	CcSEcCtD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000786	0.024	CbGpPWpGaD
Nepafenac—Dermatitis atopic—Gemcitabine—urinary bladder cancer	0.000738	0.0227	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000714	0.0218	CbGpPWpGaD
Nepafenac—Diclofenac—CXCL8—urinary bladder cancer	0.000701	0.0942	CrCbGaD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000694	0.0212	CbGpPWpGaD
Nepafenac—Cataract—Thiotepa—urinary bladder cancer	0.000682	0.021	CcSEcCtD
Nepafenac—Impaired healing—Methotrexate—urinary bladder cancer	0.000646	0.0199	CcSEcCtD
Nepafenac—Eye irritation—Fluorouracil—urinary bladder cancer	0.000629	0.0193	CcSEcCtD
Nepafenac—Ketoprofen—CXCL8—urinary bladder cancer	0.000621	0.0835	CrCbGaD
Nepafenac—Photophobia—Thiotepa—urinary bladder cancer	0.000609	0.0187	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000597	0.0183	CbGpPWpGaD
Nepafenac—Lacrimation increased—Fluorouracil—urinary bladder cancer	0.000583	0.0179	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—urinary bladder cancer	0.000576	0.0775	CrCbGaD
Nepafenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.000575	0.0176	CbGpPWpGaD
Nepafenac—Bromfenac—PTGS2—urinary bladder cancer	0.000553	0.0743	CrCbGaD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.00054	0.0165	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000535	0.0164	CbGpPWpGaD
Nepafenac—Vision blurred—Mitomycin—urinary bladder cancer	0.000532	0.0164	CcSEcCtD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000526	0.0161	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.000507	0.0155	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.000507	0.0155	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000506	0.0155	CbGpPWpGaD
Nepafenac—Photophobia—Fluorouracil—urinary bladder cancer	0.000504	0.0155	CcSEcCtD
Nepafenac—Hypertension—Mitomycin—urinary bladder cancer	0.000487	0.015	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000474	0.0145	CbGpPWpGaD
Nepafenac—Pruritus—Valrubicin—urinary bladder cancer	0.000473	0.0145	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS2—urinary bladder cancer	0.00047	0.0632	CrCbGaD
Nepafenac—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000464	0.0142	CbGpPWpGaD
Nepafenac—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.000451	0.0138	CbGpPWpGaD
Nepafenac—Lacrimation—Epirubicin—urinary bladder cancer	0.000444	0.0137	CcSEcCtD
Nepafenac—Dizziness—Valrubicin—urinary bladder cancer	0.000442	0.0136	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000437	0.0134	CbGpPWpGaD
Nepafenac—Magnesium salicylate—PTGS2—urinary bladder cancer	0.000437	0.0587	CrCbGaD
Nepafenac—Fenbufen—PTGS2—urinary bladder cancer	0.000427	0.0575	CrCbGaD
Nepafenac—Vomiting—Valrubicin—urinary bladder cancer	0.000425	0.0131	CcSEcCtD
Nepafenac—Headache—Valrubicin—urinary bladder cancer	0.000419	0.0129	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000418	0.0128	CbGpPWpGaD
Nepafenac—Lacrimation—Doxorubicin—urinary bladder cancer	0.000411	0.0127	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000408	0.0125	CbGpPWpGaD
Nepafenac—Keratitis—Epirubicin—urinary bladder cancer	0.000403	0.0124	CcSEcCtD
Nepafenac—Nausea—Valrubicin—urinary bladder cancer	0.000397	0.0122	CcSEcCtD
Nepafenac—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000395	0.0121	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000375	0.0115	CbGpPWpGaD
Nepafenac—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.000374	0.0114	CbGpPWpGaD
Nepafenac—Keratitis—Doxorubicin—urinary bladder cancer	0.000373	0.0115	CcSEcCtD
Nepafenac—Salsalate—PTGS2—urinary bladder cancer	0.000371	0.0499	CrCbGaD
Nepafenac—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000361	0.011	CbGpPWpGaD
Nepafenac—Dermatitis atopic—Epirubicin—urinary bladder cancer	0.000353	0.0109	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000353	0.0108	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000347	0.0106	CbGpPWpGaD
Nepafenac—Dermatitis atopic—Doxorubicin—urinary bladder cancer	0.000327	0.0101	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000313	0.00957	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000309	0.00945	CbGpPWpGaD
Nepafenac—Fenoprofen—PTGS2—urinary bladder cancer	0.000307	0.0413	CrCbGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000306	0.00935	CbGpPWpGaD
Nepafenac—Eye disorder—Thiotepa—urinary bladder cancer	0.000305	0.00937	CcSEcCtD
Nepafenac—Dizziness—Mitomycin—urinary bladder cancer	0.000305	0.00937	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000304	0.00931	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000298	0.0091	CbGpPWpGaD
Nepafenac—Angiopathy—Thiotepa—urinary bladder cancer	0.000296	0.0091	CcSEcCtD
Nepafenac—Immune system disorder—Thiotepa—urinary bladder cancer	0.000294	0.00906	CcSEcCtD
Nepafenac—Vomiting—Mitomycin—urinary bladder cancer	0.000293	0.00901	CcSEcCtD
Nepafenac—Headache—Mitomycin—urinary bladder cancer	0.000288	0.00888	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—urinary bladder cancer	0.000285	0.0383	CrCbGaD
Nepafenac—Lacrimation increased—Epirubicin—urinary bladder cancer	0.000284	0.00873	CcSEcCtD
Nepafenac—Sinusitis—Fluorouracil—urinary bladder cancer	0.000282	0.00867	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00028	0.00857	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000278	0.0085	CbGpPWpGaD
Nepafenac—Nausea—Mitomycin—urinary bladder cancer	0.000274	0.00842	CcSEcCtD
Nepafenac—Vision blurred—Thiotepa—urinary bladder cancer	0.000267	0.00823	CcSEcCtD
Nepafenac—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.000262	0.00807	CcSEcCtD
Nepafenac—Angiopathy—Gemcitabine—urinary bladder cancer	0.000249	0.00765	CcSEcCtD
Nepafenac—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000248	0.00762	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000246	0.00752	CbGpPWpGaD
Nepafenac—Hypertension—Thiotepa—urinary bladder cancer	0.000245	0.00754	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000242	0.00739	CbGpPWpGaD
Nepafenac—Dry eye—Epirubicin—urinary bladder cancer	0.000241	0.00743	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00024	0.00738	CcSEcCtD
Nepafenac—Eye disorder—Cisplatin—urinary bladder cancer	0.000239	0.00735	CcSEcCtD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000236	0.00723	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000235	0.0072	CbGpPWpGaD
Nepafenac—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000233	0.00717	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000231	0.00706	CbGpPWpGaD
Nepafenac—Immune system disorder—Cisplatin—urinary bladder cancer	0.000231	0.0071	CcSEcCtD
Nepafenac—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000227	0.00699	CcSEcCtD
Nepafenac—Skin disorder—Thiotepa—urinary bladder cancer	0.000225	0.00692	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000225	0.00687	CbGpPWpGaD
Nepafenac—Dry eye—Doxorubicin—urinary bladder cancer	0.000223	0.00687	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000222	0.00679	CbGpPWpGaD
Nepafenac—Vision blurred—Fluorouracil—urinary bladder cancer	0.000221	0.00681	CcSEcCtD
Nepafenac—Eye disorder—Etoposide—urinary bladder cancer	0.000219	0.00673	CcSEcCtD
Nepafenac—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000218	0.00671	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000215	0.00659	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000215	0.00656	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000213	0.0065	CbGpPWpGaD
Nepafenac—Angiopathy—Etoposide—urinary bladder cancer	0.000212	0.00654	CcSEcCtD
Nepafenac—Immune system disorder—Etoposide—urinary bladder cancer	0.000211	0.00651	CcSEcCtD
Nepafenac—Eye pain—Epirubicin—urinary bladder cancer	0.00021	0.00647	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.00021	0.00641	CbGpPWpGaD
Nepafenac—Vision blurred—Cisplatin—urinary bladder cancer	0.00021	0.00645	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000208	0.00636	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000207	0.00634	CbGpPWpGaD
Nepafenac—Hypertension—Gemcitabine—urinary bladder cancer	0.000206	0.00634	CcSEcCtD
Nepafenac—Diclofenac—PTGS2—urinary bladder cancer	0.000204	0.0275	CrCbGaD
Nepafenac—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000202	0.00621	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000202	0.00621	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.0002	0.00615	CcSEcCtD
Nepafenac—Eye pain—Doxorubicin—urinary bladder cancer	0.000194	0.00598	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000193	0.00591	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000193	0.00591	CbGpPWpGaD
Nepafenac—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000191	0.00588	CcSEcCtD
Nepafenac—Skin disorder—Gemcitabine—urinary bladder cancer	0.000189	0.00582	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000188	0.00579	CcSEcCtD
Nepafenac—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000188	0.00578	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000187	0.00572	CbGpPWpGaD
Nepafenac—Ketoprofen—PTGS2—urinary bladder cancer	0.000181	0.0244	CrCbGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000178	0.00545	CbGpPWpGaD
Nepafenac—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000178	0.00548	CcSEcCtD
Nepafenac—Skin disorder—Cisplatin—urinary bladder cancer	0.000176	0.00543	CcSEcCtD
Nepafenac—Hypertension—Etoposide—urinary bladder cancer	0.000176	0.00541	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000172	0.0053	CcSEcCtD
Nepafenac—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000171	0.00525	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000168	0.00517	CcSEcCtD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000166	0.00508	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000165	0.00509	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000165	0.00503	CbGpPWpGaD
Nepafenac—Pruritus—Thiotepa—urinary bladder cancer	0.000164	0.00504	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000162	0.00496	CbGpPWpGaD
Nepafenac—Skin disorder—Etoposide—urinary bladder cancer	0.000162	0.00497	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000161	0.00493	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00016	0.0049	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.00016	0.00489	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000157	0.00482	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000154	0.00472	CbGpPWpGaD
Nepafenac—Dizziness—Thiotepa—urinary bladder cancer	0.000153	0.00471	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000153	0.00468	CbGpPWpGaD
Nepafenac—PTGS1—prostate gland—urinary bladder cancer	0.000152	0.0904	CbGeAlD
Nepafenac—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000149	0.00457	CbGpPWpGaD
Nepafenac—Vomiting—Thiotepa—urinary bladder cancer	0.000147	0.00453	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000147	0.00449	CbGpPWpGaD
Nepafenac—PTGS2—prostate gland—urinary bladder cancer	0.000145	0.0864	CbGeAlD
Nepafenac—Headache—Thiotepa—urinary bladder cancer	0.000145	0.00446	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000144	0.00442	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000143	0.00436	CbGpPWpGaD
Nepafenac—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000141	0.00434	CcSEcCtD
Nepafenac—Pruritus—Gemcitabine—urinary bladder cancer	0.000138	0.00424	CcSEcCtD
Nepafenac—Nausea—Thiotepa—urinary bladder cancer	0.000138	0.00423	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000137	0.0042	CbGpPWpGaD
Nepafenac—Sinusitis—Epirubicin—urinary bladder cancer	0.000137	0.00422	CcSEcCtD
Nepafenac—Pruritus—Fluorouracil—urinary bladder cancer	0.000136	0.00417	CcSEcCtD
Nepafenac—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000134	0.00412	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000133	0.00407	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000132	0.00404	CbGpPWpGaD
Nepafenac—Eye disorder—Methotrexate—urinary bladder cancer	0.000131	0.00403	CcSEcCtD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000131	0.004	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00013	0.00397	CbGpPWpGaD
Nepafenac—PTGS1—seminal vesicle—urinary bladder cancer	0.000129	0.0765	CbGeAlD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000128	0.00391	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000127	0.00389	CbGpPWpGaD
Nepafenac—Angiopathy—Methotrexate—urinary bladder cancer	0.000127	0.00391	CcSEcCtD
Nepafenac—Sinusitis—Doxorubicin—urinary bladder cancer	0.000127	0.0039	CcSEcCtD
Nepafenac—Immune system disorder—Methotrexate—urinary bladder cancer	0.000127	0.0039	CcSEcCtD
Nepafenac—Dizziness—Fluorouracil—urinary bladder cancer	0.000127	0.0039	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000125	0.00382	CbGpPWpGaD
Nepafenac—Vomiting—Gemcitabine—urinary bladder cancer	0.000124	0.00381	CcSEcCtD
Nepafenac—PTGS2—seminal vesicle—urinary bladder cancer	0.000123	0.0731	CbGeAlD
Nepafenac—Eye disorder—Epirubicin—urinary bladder cancer	0.000123	0.00377	CcSEcCtD
Nepafenac—Hypersensitivity—Etoposide—urinary bladder cancer	0.000123	0.00377	CcSEcCtD
Nepafenac—Headache—Gemcitabine—urinary bladder cancer	0.000122	0.00375	CcSEcCtD
Nepafenac—Vomiting—Fluorouracil—urinary bladder cancer	0.000122	0.00375	CcSEcCtD
Nepafenac—Headache—Fluorouracil—urinary bladder cancer	0.00012	0.00369	CcSEcCtD
Nepafenac—Angiopathy—Epirubicin—urinary bladder cancer	0.000119	0.00366	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000119	0.00364	CbGpPWpGaD
Nepafenac—Immune system disorder—Epirubicin—urinary bladder cancer	0.000119	0.00365	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000118	0.00361	CbGpPWpGaD
Nepafenac—Pruritus—Etoposide—urinary bladder cancer	0.000118	0.00362	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000117	0.00356	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000116	0.00355	CbGpPWpGaD
Nepafenac—Nausea—Gemcitabine—urinary bladder cancer	0.000116	0.00356	CcSEcCtD
Nepafenac—Vomiting—Cisplatin—urinary bladder cancer	0.000115	0.00355	CcSEcCtD
Nepafenac—Vision blurred—Methotrexate—urinary bladder cancer	0.000115	0.00354	CcSEcCtD
Nepafenac—Nausea—Fluorouracil—urinary bladder cancer	0.000114	0.0035	CcSEcCtD
Nepafenac—Eye disorder—Doxorubicin—urinary bladder cancer	0.000113	0.00349	CcSEcCtD
Nepafenac—PTGS1—epithelium—urinary bladder cancer	0.000112	0.0664	CbGeAlD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.000111	0.00341	CbGpPWpGaD
Nepafenac—Angiopathy—Doxorubicin—urinary bladder cancer	0.00011	0.00339	CcSEcCtD
Nepafenac—Dizziness—Etoposide—urinary bladder cancer	0.00011	0.00338	CcSEcCtD
Nepafenac—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00011	0.00337	CcSEcCtD
Nepafenac—Nausea—Cisplatin—urinary bladder cancer	0.000108	0.00332	CcSEcCtD
Nepafenac—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000108	0.064	CbGeAlD
Nepafenac—Vision blurred—Epirubicin—urinary bladder cancer	0.000108	0.00331	CcSEcCtD
Nepafenac—PTGS2—epithelium—urinary bladder cancer	0.000107	0.0635	CbGeAlD
Nepafenac—Vomiting—Etoposide—urinary bladder cancer	0.000106	0.00325	CcSEcCtD
Nepafenac—Headache—Etoposide—urinary bladder cancer	0.000104	0.00321	CcSEcCtD
Nepafenac—PTGS1—renal system—urinary bladder cancer	0.000104	0.0616	CbGeAlD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000103	0.00318	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000103	0.00316	CbGpPWpGaD
Nepafenac—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000103	0.0612	CbGeAlD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000101	0.0031	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	0.000101	0.00309	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.0001	0.00307	CbGpPWpGaD
Nepafenac—Vision blurred—Doxorubicin—urinary bladder cancer	9.96e-05	0.00307	CcSEcCtD
Nepafenac—PTGS2—renal system—urinary bladder cancer	9.91e-05	0.0589	CbGeAlD
Nepafenac—Nausea—Etoposide—urinary bladder cancer	9.88e-05	0.00304	CcSEcCtD
Nepafenac—Hypertension—Epirubicin—urinary bladder cancer	9.86e-05	0.00303	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	9.84e-05	0.00301	CbGpPWpGaD
Nepafenac—Nervous system disorder—Methotrexate—urinary bladder cancer	9.77e-05	0.00301	CcSEcCtD
Nepafenac—PTGS2—urethra—urinary bladder cancer	9.74e-05	0.0578	CbGeAlD
Nepafenac—Skin disorder—Methotrexate—urinary bladder cancer	9.68e-05	0.00298	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.66e-05	0.00297	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	9.52e-05	0.00291	CbGpPWpGaD
Nepafenac—Dry mouth—Epirubicin—urinary bladder cancer	9.51e-05	0.00293	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	9.17e-05	0.0028	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	9.15e-05	0.0028	CbGpPWpGaD
Nepafenac—Nervous system disorder—Epirubicin—urinary bladder cancer	9.14e-05	0.00281	CcSEcCtD
Nepafenac—Hypertension—Doxorubicin—urinary bladder cancer	9.13e-05	0.00281	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	9.06e-05	0.00277	CbGpPWpGaD
Nepafenac—Skin disorder—Epirubicin—urinary bladder cancer	9.06e-05	0.00279	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.98e-05	0.00275	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.94e-05	0.00275	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	8.93e-05	0.00273	CbGpPWpGaD
Nepafenac—Dry mouth—Doxorubicin—urinary bladder cancer	8.8e-05	0.00271	CcSEcCtD
Nepafenac—PTGS1—Metabolism—GSTO2—urinary bladder cancer	8.67e-05	0.00265	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NAT1—urinary bladder cancer	8.67e-05	0.00265	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.6e-05	0.00265	CcSEcCtD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.53e-05	0.00261	CbGpPWpGaD
Nepafenac—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.46e-05	0.0026	CcSEcCtD
Nepafenac—Skin disorder—Doxorubicin—urinary bladder cancer	8.38e-05	0.00258	CcSEcCtD
Nepafenac—PTGS1—female reproductive system—urinary bladder cancer	8.3e-05	0.0493	CbGeAlD
Nepafenac—PTGS2—Disease—GSTO2—urinary bladder cancer	8.22e-05	0.00251	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	8.05e-05	0.00246	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.05e-05	0.00248	CcSEcCtD
Nepafenac—PTGS2—female reproductive system—urinary bladder cancer	7.94e-05	0.0472	CbGeAlD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.93e-05	0.00243	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	7.93e-05	0.00243	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.9e-05	0.00242	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	7.9e-05	0.00241	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.87e-05	0.00241	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	7.69e-05	0.00235	CbGpPWpGaD
Nepafenac—PTGS1—vagina—urinary bladder cancer	7.51e-05	0.0446	CbGeAlD
Nepafenac—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	7.5e-05	0.00229	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.45e-05	0.00229	CcSEcCtD
Nepafenac—Hypersensitivity—Methotrexate—urinary bladder cancer	7.34e-05	0.00226	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	7.3e-05	0.00223	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	7.28e-05	0.00223	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	7.26e-05	0.00222	CbGpPWpGaD
Nepafenac—PTGS2—vagina—urinary bladder cancer	7.18e-05	0.0427	CbGeAlD
Nepafenac—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	7.14e-05	0.00218	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.09e-05	0.00217	CbGpPWpGaD
Nepafenac—Pruritus—Methotrexate—urinary bladder cancer	7.05e-05	0.00217	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.9e-05	0.00211	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTO2—urinary bladder cancer	6.88e-05	0.00211	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NAT1—urinary bladder cancer	6.88e-05	0.00211	CbGpPWpGaD
Nepafenac—Hypersensitivity—Epirubicin—urinary bladder cancer	6.87e-05	0.00211	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.81e-05	0.00208	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.77e-05	0.00207	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	6.74e-05	0.00206	CbGpPWpGaD
Nepafenac—Pruritus—Epirubicin—urinary bladder cancer	6.6e-05	0.00203	CcSEcCtD
Nepafenac—Dizziness—Methotrexate—urinary bladder cancer	6.59e-05	0.00203	CcSEcCtD
Nepafenac—PTGS1—Metabolism—PRSS3—urinary bladder cancer	6.57e-05	0.00201	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SLC19A1—urinary bladder cancer	6.39e-05	0.00195	CbGpPWpGaD
Nepafenac—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.36e-05	0.00196	CcSEcCtD
Nepafenac—Vomiting—Methotrexate—urinary bladder cancer	6.34e-05	0.00195	CcSEcCtD
Nepafenac—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	6.3e-05	0.00193	CbGpPWpGaD
Nepafenac—Headache—Methotrexate—urinary bladder cancer	6.24e-05	0.00192	CcSEcCtD
Nepafenac—PTGS2—Disease—PRSS3—urinary bladder cancer	6.23e-05	0.00191	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	6.2e-05	0.0019	CbGpPWpGaD
Nepafenac—Dizziness—Epirubicin—urinary bladder cancer	6.17e-05	0.0019	CcSEcCtD
Nepafenac—Pruritus—Doxorubicin—urinary bladder cancer	6.1e-05	0.00188	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	6.02e-05	0.00184	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HDAC4—urinary bladder cancer	5.94e-05	0.00182	CbGpPWpGaD
Nepafenac—Vomiting—Epirubicin—urinary bladder cancer	5.93e-05	0.00182	CcSEcCtD
Nepafenac—Nausea—Methotrexate—urinary bladder cancer	5.92e-05	0.00182	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	5.88e-05	0.0018	CbGpPWpGaD
Nepafenac—Headache—Epirubicin—urinary bladder cancer	5.84e-05	0.0018	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.78e-05	0.00177	CbGpPWpGaD
Nepafenac—Dizziness—Doxorubicin—urinary bladder cancer	5.71e-05	0.00176	CcSEcCtD
Nepafenac—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	5.67e-05	0.00173	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	5.6e-05	0.00171	CbGpPWpGaD
Nepafenac—Nausea—Epirubicin—urinary bladder cancer	5.54e-05	0.0017	CcSEcCtD
Nepafenac—Vomiting—Doxorubicin—urinary bladder cancer	5.49e-05	0.00169	CcSEcCtD
Nepafenac—Headache—Doxorubicin—urinary bladder cancer	5.41e-05	0.00166	CcSEcCtD
Nepafenac—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	5.35e-05	0.00164	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.27e-05	0.00161	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TYMP—urinary bladder cancer	5.25e-05	0.00161	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PRSS3—urinary bladder cancer	5.22e-05	0.0016	CbGpPWpGaD
Nepafenac—Nausea—Doxorubicin—urinary bladder cancer	5.12e-05	0.00158	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.1e-05	0.00156	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.05e-05	0.00154	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.94e-05	0.00151	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.94e-05	0.00151	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.92e-05	0.00151	CbGpPWpGaD
Nepafenac—PTGS1—lymph node—urinary bladder cancer	4.86e-05	0.0289	CbGeAlD
Nepafenac—PTGS1—Metabolism—NAT2—urinary bladder cancer	4.75e-05	0.00145	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LIG1—urinary bladder cancer	4.72e-05	0.00144	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.7e-05	0.00144	CbGpPWpGaD
Nepafenac—PTGS2—lymph node—urinary bladder cancer	4.64e-05	0.0276	CbGeAlD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.57e-05	0.0014	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.18e-05	0.00128	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TYMP—urinary bladder cancer	4.17e-05	0.00128	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—RRM2—urinary bladder cancer	4.1e-05	0.00125	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.09e-05	0.00125	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.01e-05	0.00123	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4e-05	0.00122	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.81e-05	0.00117	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.8e-05	0.00116	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.8e-05	0.00116	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.78e-05	0.00116	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.78e-05	0.00115	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.77e-05	0.00115	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.68e-05	0.00113	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.63e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ENO2—urinary bladder cancer	3.6e-05	0.0011	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RBX1—urinary bladder cancer	3.41e-05	0.00104	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.36e-05	0.00103	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.26e-05	0.000996	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NQO1—urinary bladder cancer	3.06e-05	0.000936	CbGpPWpGaD
Nepafenac—PTGS2—Disease—JAG1—urinary bladder cancer	3.05e-05	0.000934	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HPGDS—urinary bladder cancer	3.02e-05	0.000922	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ENO2—urinary bladder cancer	3.02e-05	0.000922	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3e-05	0.000917	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.97e-05	0.000908	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.92e-05	0.000894	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.88e-05	0.000881	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.59e-05	0.000792	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.55e-05	0.000781	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.47e-05	0.000756	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.43e-05	0.000743	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.37e-05	0.000726	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.35e-05	0.000718	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.35e-05	0.000718	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.25e-05	0.000687	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NCOR1—urinary bladder cancer	2.22e-05	0.00068	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.21e-05	0.000675	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERCC2—urinary bladder cancer	2.09e-05	0.00064	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MTHFR—urinary bladder cancer	2.07e-05	0.000634	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.06e-05	0.000629	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTP1—urinary bladder cancer	2.03e-05	0.00062	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTHFR—urinary bladder cancer	1.97e-05	0.000601	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.96e-05	0.0006	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TERT—urinary bladder cancer	1.96e-05	0.0006	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.88e-05	0.000576	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.00057	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.00057	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGFR3—urinary bladder cancer	1.8e-05	0.00055	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.78e-05	0.000546	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000536	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.68e-05	0.000514	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.65e-05	0.000504	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.62e-05	0.000494	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CREBBP—urinary bladder cancer	1.53e-05	0.000468	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RHOA—urinary bladder cancer	1.39e-05	0.000424	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.33e-05	0.000408	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.32e-05	0.000405	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000392	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB2—urinary bladder cancer	1.28e-05	0.000392	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.15e-05	0.000353	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—EP300—urinary bladder cancer	1.1e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.1e-05	0.000335	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PTEN—urinary bladder cancer	1.09e-05	0.000334	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EP300—urinary bladder cancer	1.04e-05	0.000319	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SRC—urinary bladder cancer	1.01e-05	0.00031	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTEN—urinary bladder cancer	9.16e-06	0.00028	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MYC—urinary bladder cancer	9.09e-06	0.000278	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGFR—urinary bladder cancer	8.89e-06	0.000272	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—EP300—urinary bladder cancer	8.73e-06	0.000267	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KRAS—urinary bladder cancer	8.4e-06	0.000257	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HRAS—urinary bladder cancer	7.14e-06	0.000218	CbGpPWpGaD
